Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms. / Holmström, Morten Orebo; Hasselbalch, Hans Carl; Andersen, Mads Hald.
I: Cancers, Bind 12, Nr. 7, 1763, 2020, s. 1-21.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms
AU - Holmström, Morten Orebo
AU - Hasselbalch, Hans Carl
AU - Andersen, Mads Hald
PY - 2020
Y1 - 2020
N2 - Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPN) are neoplastic diseases of the hematopoietic stem cells in the bone marrow. MPN are characterized by chronic inflammation and immune dysregulation. Of interest, the potent immunostimulatory cytokine interferon-α has been used to treat MPN for decades. A deeper understanding of the anti-cancer immune response and of the different immune regulatory mechanisms in patients with MPN has paved the way for an increased perception of the potential of cancer immunotherapy in MPN. Therapeutic vaccination targeting the driver mutations in MPN is one recently described potential new treatment modality. Furthermore, T cells can directly react against regulatory immune cells because they recognize proteins like arginase and programmed death ligand 1 (PD-L1). Therapeutic vaccination with arginase or PD-L1 therefore offers a novel way to directly affect immune inhibitory pathways, potentially altering tolerance to tumor antigens like mutant CALR and mutant JAK2. Other therapeutic options that could be used in concert with therapeutic cancer vaccines are immune checkpoint–blocking antibodies and interferon-α. For more advanced MPN, adoptive cellular therapy is a potential option that needs more preclinical investigation. In this review, we summarize current knowledge about the immune system in MPN and discuss the many opportunities for anti-cancer immunotherapy in patients with MPN.
AB - Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPN) are neoplastic diseases of the hematopoietic stem cells in the bone marrow. MPN are characterized by chronic inflammation and immune dysregulation. Of interest, the potent immunostimulatory cytokine interferon-α has been used to treat MPN for decades. A deeper understanding of the anti-cancer immune response and of the different immune regulatory mechanisms in patients with MPN has paved the way for an increased perception of the potential of cancer immunotherapy in MPN. Therapeutic vaccination targeting the driver mutations in MPN is one recently described potential new treatment modality. Furthermore, T cells can directly react against regulatory immune cells because they recognize proteins like arginase and programmed death ligand 1 (PD-L1). Therapeutic vaccination with arginase or PD-L1 therefore offers a novel way to directly affect immune inhibitory pathways, potentially altering tolerance to tumor antigens like mutant CALR and mutant JAK2. Other therapeutic options that could be used in concert with therapeutic cancer vaccines are immune checkpoint–blocking antibodies and interferon-α. For more advanced MPN, adoptive cellular therapy is a potential option that needs more preclinical investigation. In this review, we summarize current knowledge about the immune system in MPN and discuss the many opportunities for anti-cancer immunotherapy in patients with MPN.
KW - CALR
KW - Cancer immune therapy
KW - Cancer vaccines
KW - Immunoediting
KW - Immunosurveillance
KW - JAK2
KW - Myeloproliferative neoplasms
KW - Neo-antigens
U2 - 10.3390/cancers12071763
DO - 10.3390/cancers12071763
M3 - Review
C2 - 32630667
AN - SCOPUS:85087413597
VL - 12
SP - 1
EP - 21
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 7
M1 - 1763
ER -
ID: 244919075